ClinicalTrials.gg
CompletedNCT05612581Updated Feb 9, 2026Results posted

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

A Phase 1/2 interventional study of VIR-3434 and VIR-2218 in Hepatitis B, Chronic, sponsored by Vir Biotechnology, Inc.. Completed at 15 sites in 6 countries. Open to participants aged 18 Years to 66 Years. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Vir Biotechnology, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 66 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Hepatitis B, Chronic with a site in France — 8 open to participants now, 10 under way, none of them phase 3. Hepatitis B, Chronic · France.

Enrollment
40th of 44
33 · median 135
Started
2023
with 1 other
Phase 1/2
6 of 54
1 open now
Registered
43rd of 54
by date

Among the 54 studies in Hepatitis B, Chronic with a site in France, this one is the 40th largest by enrollment of the 44 interventional ones that give a count, is one of 2 that started in 2023, is one of 6 in phase 1/2, and was the 43rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

8 of the 54 studies in Hepatitis B, Chronic with a site in France are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 66 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Hepatitis B, Chronic with a site in France, or all of them as a file.
02

Study summary

This is a Phase 1b/2 platform study framework to evaluate the safety and efficacy of investigational candidate(s) and their combinations as potential treatments for adults with chronic hepatitis B virus infection.

Read the detailed description

VIR-SHB1-V201 (STRIVE) Sub-Protocol A is a Phase 2 study under the PREVAIL platform trial. This is a multi-center, open-label study designed to evaluate the safety and efficacy of regimens containing VIR-3434, VIR-2218, PEGASYS (PEG-IFNα), and nucleotide reverse transcriptase inhibitors (NRTI) in noncirrhotic adult participants with chronic HBV infection that have not received prior NRTI or PEGASYS treatment.

VIR-SHB1-V202 (THRIVE) Sub-Protocol B is a Phase 2 study under the PREVAIL platform trial. This is a multi-center open-label study designed to evaluate the safety and efficacy of regimens containing VIR-3434 and NRTI with or without VIR-2218 in noncirrhotic adult participants with low viral burden of chronic HBV infection.

03

Conditions studied

  • Hepatitis B, Chronic

Keywords

  • Hepatitis B Virus
  • Chronic Hepatitis B
  • HBV
  • Hepatitis
04

Who can participate

Ages eligible
18 Years to 66 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ages 18 or older
  • Chronic infection for >/= 6 months
  • Chronic HBV infection defined as a positive serum HBsAg, HBV DNA, or HBeAg on 2 occasions at least 6 months apart based on previous or current laboratory documentation
  • STRIVE: HBeAg positive or negative, HBV DNA > 2,000 IU/mL, > and ≤ 5x ULN
  • THRIVE: Must be/have the following, within the 1-year period prior to screening: HBeAg negative, HBV DNA ≤ 2,000 IU/mL, ALT ≤ ULN

Exclusion criteria

Exclusion Criteria:

  • Any chronic or acute medical condition that makes the participant unsuitable for participation
  • History of clinically significant liver disease from non- etiology
  • History or current evidence of hepatic decompensation
  • Co-infection with (HIV), hepatitis A virus (HAV), virus (HCV), hepatitis D virus (HDV) or hepatitis E virus (HEV).
  • History or clinical evidence of alcohol or drug abuse
  • STRIVE and THRIVE: Significant fibrosis or cirrhosis
  • STRIVE and THRIVE: History of immune complex disease
  • STRIVE and THRIVE: History of disorder
  • STRIVE and THRIVE: History of allergic reactions, , or intolerance to monoclonal antibodies, antibody fragments, or any of VIR-3434
  • STRIVE: Prior NRTI or PEG-IFN therapy
  • STRIVE: History of known to any interferon product
  • THRIVE: Prior NRTI therapy \< 24 weeks of study or any prior PEG-IFN therapy
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    STRIVE: Cohort 1a (VIR-3434 + TDF)

    Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total

    Drug: VIR-3434 · Drug: TDF

  • Experimental
    STRIVE: Cohort 2a (VIR-3434 + TDF)

    Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks total

    Drug: VIR-3434 · Drug: TDF

  • Experimental
    STRIVE: Cohort 3a (VIR-3434 + TDF)

    Participants will receive combination therapy with VIR-3434 + TDF for 36 or 40 weeks total

    Drug: VIR-3434 · Drug: TDF

  • Experimental
    STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)

    Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 20 or 44 weeks total

    Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF

  • Experimental
    STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)

    Participants will receive combination therapy with VIR-3434 + VIR-2218 +TDF + PEG-IFNα for 48 weeks total

    Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF · Drug: PEG-IFNα

  • Experimental
    THRIVE: Cohort 1b (VIR-3434 + TDF)

    Participants will receive combination therapy with VIR-3434 + TDF for 44 weeks

    Drug: VIR-3434 · Drug: TDF

  • Experimental
    THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)

    Participants will receive combination therapy with VIR-3434 + VIR-2218 + TDF for 44 weeks total

    Drug: VIR-3434 · Drug: VIR-2218 · Drug: TDF

Interventions

  • VIR-3434 given by subcutaneous injection

    Also known as: Tobevibart

  • VIR-2218 given by subcutaneous injection

    Also known as: Elebsiran

  • DrugTDF

    TDF given orally

  • PEG-IFNα given by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment

    Time frame: Up to 48 weeks

Secondary outcomes

  1. STRIVE and THRIVE: Proportion of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 96 weeks

  2. STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at End of Treatment

    Time frame: Up to 48 weeks

  3. STRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at 24 Weeks Post-end of Treatment

    Time frame: Up to 72 weeks

  4. STRIVE and THRIVE: Serum HBsAg Levels and Change From Baseline Across Timepoints in the Study

    Time frame: Up to 96 weeks

  5. STRIVE and THRIVE: Serum HBsAg Level at Nadir During the Study

    Time frame: Up to 96 weeks

  6. STRIVE and THRIVE: Time to Achieve Nadir of Serum HBsAg During the Study

    Time frame: Up to 96 weeks

  7. STRIVE and THRIVE: Time to Achieve Serum HBsAg Loss (< 0.05 IU/mL)

    Time frame: Up to 96 weeks

  8. STRIVE and THRIVE: Proportion of Participants With HBsAg Loss With Anti-HBs Seroconversion at End of Treatment and at 24 Weeks Post-end of Treatment

    Time frame: Up to 76 weeks

  9. STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit

    Time frame: Up to 96 weeks

  10. STRIVE: Proportion of Participants With HBsAg Loss (<0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment

    Time frame: Up to 72 weeks

  11. STRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit

    Time frame: Up to 96 weeks

  12. STRIVE: For HBeAg-positive Participants: Proportion of Participants With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion

    Time frame: Up to 72 weeks

  13. STRIVE: Incidence and Titers of Anti-drug Antibodies (ADA; if Applicable) to VIR-3434

    Time frame: Up to 96 weeks

  14. STRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study

    Time frame: Up to 96 weeks

  15. STRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ) Across Timepoints in the Study

    Time frame: Up to 96 weeks

  16. STRIVE: Proportion of Participants Achieving ALT ≤ ULN Across Timepoints in the Study

    Time frame: Up to 96 weeks

  17. THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks

    Time frame: Up to 92 weeks

  18. THRIVE: Proportion of Participants Achieving HBsAg Loss (< 0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment

    Time frame: Up to 44 weeks

  19. THRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks

    Time frame: Up to 68 weeks

  20. THRIVE: Incidence and Titers of ADA (if Applicable) to VIR-3434

    Time frame: Up to 92 weeks

  21. THRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study

    Time frame: Up to 92 weeks

  22. THRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ)

    Time frame: Up to 92 weeks

07

Results

Posted Nov 26, 2025

Participant flow

Participant flow — Overall Study
MilestoneSTRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)
Started000160017
Completed000110017
Not completed0005000

Outcome measures

PrimarySTRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment
Time frame:
Up to 48 weeks
Reported as:
Count of participants · Participants
STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment
ParticipantsSTRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)
STRIVE and THRIVE: Proportion of Participants Achieving Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) at the End of Treatment———1——4
SecondarySTRIVE and THRIVE: Proportion of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at End of Treatment
Time frame:
Up to 48 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Proportion of Participants With Serum HBsAg ≤ 10 IU/mL at 24 Weeks Post-end of Treatment
Time frame:
Up to 72 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Serum HBsAg Levels and Change From Baseline Across Timepoints in the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Serum HBsAg Level at Nadir During the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Time to Achieve Nadir of Serum HBsAg During the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Time to Achieve Serum HBsAg Loss (< 0.05 IU/mL)
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE and THRIVE: Proportion of Participants With HBsAg Loss With Anti-HBs Seroconversion at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame:
Up to 76 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Proportion of Participants With HBsAg Loss (<0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame:
Up to 72 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at the F48 Follow-Up Visit
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: For HBeAg-positive Participants: Proportion of Participants With HBeAg Loss (Undetectable HBeAg) and/or Anti-HBe Seroconversion
Time frame:
Up to 72 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Incidence and Titers of Anti-drug Antibodies (ADA; if Applicable) to VIR-3434
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ) Across Timepoints in the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondarySTRIVE: Proportion of Participants Achieving ALT ≤ ULN Across Timepoints in the Study
Time frame:
Up to 96 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) With HBsAg Loss (< 0.05 IU/mL) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks
Time frame:
Up to 92 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Proportion of Participants Achieving HBsAg Loss (< 0.05 IU/mL) at End of Treatment and at 24 Weeks Post-end of Treatment
Time frame:
Up to 44 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Proportion of Participants Achieving Sustained Suppression of HBV DNA (< LLOQ) After Discontinuation of All Treatment at 24 Weeks and at 48 Weeks
Time frame:
Up to 68 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Incidence and Titers of ADA (if Applicable) to VIR-3434
Time frame:
Up to 92 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Mean Change in Serum HBsAg Level From Baseline Across Timepoints in the Study
Time frame:
Up to 92 weeks

Results for this outcome have not been posted.

SecondaryTHRIVE: Proportion of Participants Achieving HBV DNA (< LLOQ)
Time frame:
Up to 92 weeks

Results for this outcome have not been posted.

Adverse events

Collected over 48 Weeks. Non-serious events are listed at a 1.25% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
STRIVE: Cohort 1a (VIR-3434 + TDF)———
STRIVE: Cohort 2a (VIR-3434 + TDF)———
STRIVE: Cohort 3a (VIR-3434 + TDF)———
STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)—0/16 (0%)11/16 (68.8%)
STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)0/16 (0%)——
THRIVE: Cohort 1b (VIR-3434 + TDF)———
THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)0/17 (0%)1/17 (5.9%)12/17 (70.6%)
Most frequent serious events
Most frequent serious events
EventSTRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)
NeutropeniaBlood and lymphatic system disorders———0/16——1/17
Most frequent other events
Showing 10 of 45
Most frequent other events
EventSTRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)
HeadacheNervous system disorders———5/16——2/17
Influenza like illnessGeneral disorders———0/16——4/17
Alpha 1 foetoprotein increasedInvestigations———3/16——0/17
ChillsGeneral disorders———2/16——2/17
FatigueGeneral disorders———2/16——2/17
Injection site erythemaGeneral disorders———2/16——1/17
Injection site painGeneral disorders———2/16——0/17
MyalgiaMusculoskeletal and connective tissue disorders———2/16——2/17
Upper respiratory tract infectionInfections and infestations———2/16——1/17
NauseaGastrointestinal disorders———2/16——1/17

Baseline characteristics

cohort 1a, 2a,3a, 5a and 1b were not open for enrollment

Age, Categorical
Age, Categorical(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
<=18 years00000000
Between 18 and 65 years00016001733
>=65 years00000000
Age, Continuous
Age, Continuous(years)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
STRIVE: Cohort 4a———43.3 ± 9.67——0 ± 043.3 ± 9.67
THRIVE: Cohort 2b———0 ± 0——48.4 ± 9.7848.4 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
Female———10——919
Male———6——814
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
Hispanic or Latino———0——00
Not Hispanic or Latino———16——1733
Unknown or Not Reported———0——00
Race (NIH/OMB)
Race (NIH/OMB)(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
American Indian or Alaska Native———0——00
Asian———6——713
Native Hawaiian or Other Pacific Islander———0——00
Black or African American———2——57
White———7——512
More than one race———0——00
Unknown or Not Reported———1——01
Region of Enrollment
Region of Enrollment(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
New Zealand———0——00
South Korea———1——56
Romania———6——28
Hong Kong———4——26
United Kingdom———3——36
Moldova———0——22
France———2——35
Thailand———0——00
Hepatitis B surface antigen (Log10 IU/mL)
Hepatitis B surface antigen (Log10 IU/mL)(Log10 IU/mL)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
STRIVE: Cohort 4a———3.64 ± 0.72——0 ± 03.64 ± 0.72
THRIVE: Cohort 2b———0 ± 0——3.12 ± 0.663.12 ± 0.66
Hepatitis B e antigen status
Hepatitis B e antigen status(Participants)STRIVE: Cohort 1a (VIR-3434 + TDF)STRIVE: Cohort 2a (VIR-3434 + TDF)STRIVE: Cohort 3a (VIR-3434 + TDF)STRIVE: Cohort 4a (VIR-3434 + VIR-2218 + TDF)STRIVE: Cohort 5a (VIR-3434 + VIR-2218 + TDF + PEG-IFNα)THRIVE: Cohort 1b (VIR-3434 + TDF)THRIVE: Cohort 2b (VIR-3434 + VIR-2218 + TDF)Total
HBeAg positive———3——03
HBeAg negative———13——1730

2 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Investigative Site
    Clichy, 92110, France
  • Investigative Site
    Nice, 06200, France
  • Investigative Site
    Rennes, 35000, France
  • Investigative Site
    Toulouse, 31000, France
  • Investigative Site
    Hong Kong, Sha Tin, Hong Kong
  • Investigative Site
    Hong Kong, Hong Kong
  • Investigative Site
    Chisinau, MD 2025, Moldova
  • Investigative Site
    Bucharest, 021105, Romania
  • Investigative Site
    Busan, 49241, South Korea
  • Investigative Site
    Seoul, 5505, South Korea
  • Investigative Site
    Yangsan, 50612, South Korea
  • Investigative Site
    Glasgow, G4 0SF, United Kingdom
  • Investigative Site
    London, EC1A 7BE, United Kingdom
  • Investigative Site
    London, SE5 9RS, United Kingdom
  • Investigative Site
    Manchester, M8 5RB, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Oct 2024, 17 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 10, 2022
StartActual
May 10, 2023
Primary completionActual
Oct 15, 2024
CompletionActual
Aug 19, 2025
Results first posted
Nov 26, 2025
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05612581
Responsible party
Sponsor
First posted
Nov 10, 2022
Start date
May 10, 2023
Primary completion
Oct 15, 2024
Completion
Aug 19, 2025
Results posted
Nov 26, 2025
Last update
Feb 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tobevibart

Start the discussion